Capital International Inc. CA Acquires New Stake in Illumina, Inc. (NASDAQ:ILMN)

Capital International Inc. CA acquired a new position in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm acquired 31,817 shares of the life sciences company's stock, valued at approximately $4,252,000.

A number of other hedge funds also recently added to or reduced their stakes in ILMN. Capital World Investors raised its stake in shares of Illumina by 408.6% during the 4th quarter. Capital World Investors now owns 18,025,301 shares of the life sciences company's stock worth $2,408,721,000 after acquiring an additional 14,481,232 shares in the last quarter. WCM Investment Management LLC raised its position in Illumina by 26.6% during the fourth quarter. WCM Investment Management LLC now owns 4,129,855 shares of the life sciences company's stock valued at $551,625,000 after acquiring an additional 867,673 shares in the last quarter. Bank of New York Mellon Corp lifted its stake in shares of Illumina by 0.8% in the 4th quarter. Bank of New York Mellon Corp now owns 3,402,057 shares of the life sciences company's stock valued at $454,617,000 after purchasing an additional 27,618 shares during the period. Norges Bank acquired a new position in shares of Illumina during the 4th quarter worth approximately $228,714,000. Finally, Bessemer Group Inc. grew its position in shares of Illumina by 32,837.5% in the fourth quarter. Bessemer Group Inc. now owns 1,348,131 shares of the life sciences company's stock valued at $180,152,000 after purchasing an additional 1,344,038 shares during the period. 89.42% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several analysts recently commented on ILMN shares. Robert W. Baird dropped their price target on Illumina from $127.00 to $90.00 and set a "neutral" rating for the company in a research report on Wednesday, March 5th. Citigroup reduced their price target on shares of Illumina from $90.00 to $85.00 and set a "neutral" rating on the stock in a research report on Monday, April 7th. Morgan Stanley lowered their target price on shares of Illumina from $150.00 to $136.00 and set an "equal weight" rating for the company in a research note on Tuesday, February 11th. TD Cowen downgraded Illumina from a "buy" rating to a "hold" rating and cut their price objective for the company from $177.00 to $140.00 in a report on Friday, February 7th. Finally, Stephens reissued an "overweight" rating and issued a $156.00 price target on shares of Illumina in a research report on Tuesday, March 11th. One analyst has rated the stock with a sell rating, ten have given a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Illumina has an average rating of "Moderate Buy" and an average target price of $138.70.

Illumina Stock Performance

ILMN stock traded down $0.26 on Friday, hitting $77.35. The company's stock had a trading volume of 1,424,483 shares, compared to its average volume of 2,280,770. The company has a current ratio of 1.77, a quick ratio of 1.42 and a debt-to-equity ratio of 0.63. Illumina, Inc. has a 1 year low of $68.70 and a 1 year high of $156.66. The firm has a 50 day moving average of $82.02 and a two-hundred day moving average of $118.20. The stock has a market cap of $12.24 billion, a price-to-earnings ratio of -10.07, a price-to-earnings-growth ratio of 1.60 and a beta of 1.38.

Illumina (NASDAQ:ILMN - Get Free Report) last announced its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing analysts' consensus estimates of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. Equities analysts predict that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.